Researchers have developed a new patient-reported outcome questionnaire to assess symptoms and the impacts to daily life associated with cold agglutinin disease (CAD). Called the CAD-Symptoms and Impact Questionnaire (CAD-SIQ), it was developed by analyzing responses from patient interviews. Reactions to cold environments and fatigue were the most commonly…
Dianthus Therapeutics plans to launch a proof-of-concept clinical trial of its therapy candidate DNTH103 in 2024 to test the efficacy of the complement inhibitor in people with cold agglutinin disease (CAD). Data from the trial would be expected in the second half of next year. Funding for the…
The induced reduction in body temperature during an emergency surgery to replace a damaged heart component revealed the presence of mild cold agglutinin disease (CAD) in a woman in India, a study reports. The case study, “Cardiopulmonary Bypass Surgery-Cold Alert!,” was published in Annals of Cardiac Anaesthesia.
Two infections complicated the case of a woman who had cold agglutinin disease (CAD) secondary to a rare autoimmune disorder called mixed connective tissue disease (MCTD). The woman was treated for a tuberculosis (TB) lung infection, after which immunosuppressant therapies for CAD and MCTD triggered a second viral infection,…
Among people who meet the criteria for a blood condition called IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), those with cold agglutinin disease (CAD) show distinct clinical and laboratory features from those without, a study shows. IgM-MGUS is marked by the excessive production of immunoglobulin M (IgM), a type…
Four rare disease advocacy groups have been chosen by the National Organization for Rare Disorders (NORD) to take part in IAMRARE, a program that will help them launch their own patient-powered natural history studies. Rare diseases, including cold agglutinin disease (CAD) often are poorly understood, and there…
Blood transfusions may be challenging in children with cold agglutinin disease (CAD), but should remain an option for those with severe disease, a small study in India suggests. Most of the eight children with CAD in the study received a blood transfusion, but none were complete matches in terms…
Enrollment for a Phase 1b basket clinical trial of povetacicept (ALPN-303), an experimental anti-inflammatory therapy, for adults with cold agglutinin disease (CAD) and other autoimmune cytopenias is expected to start in the coming months. That’s according to a corporate update from the treatment’s developer, Alpine Immune Sciences. Basket…
A treatment to reduce the activation of the immune complement system didn’t increase the effectiveness of red blood cell transfusions in people with severe cold agglutinin disease (CAD) and other complement-mediated autoimmune hemolytic anemia (CM-AIHA). That’s according to a small, proof-of-concept Phase 2 clinical trial (EudraCT2012-003710-13) that found…
A Phase 1 trial testing Annexon Biosciences’ oral treatment candidate ANX1502 — for complement-mediated autoimmune disorders such as cold agglutinin disease (CAD) — in healthy volunteers has moved to its multiple-dosing phase. The company is planning to launch a proof-of-concept study of ANX1502 in people with CAD later…
Get regular updates to your inbox.